natgillin/translations-raw huggingface dataset:
An emollient is an oleaginous or oily substance which helps to smooth and soften the skin, and may also reduce its roughness, cracking or irritation. 
Emolijens je uljasta ili uljna tvar koja pomaže izgladiti i omekšati kožu, i može također smanjiti njenu grubost, pucanje ili iritaciju.
The air cleaner according to claim 1, wherein the filter layer has at least one frameless, open circumferential section on which the air flow flows through the open circumferential side of the filter layer wherein the frameless, open circumferential section of the filter layer is developed free of any flow guiding systems such as delimitation walls and similar systems. 
Filtarski modul sukladno jednom od prethodnih zahtjeva, pri čemu slojevi filtara (4) uključuju najmanje jedan dio bez okvira, koji se nalazi bočno od slojeva filtara (4) i kroz koji zrak može slobodno protjecati, pri čemu je taj dio dizajniran tako da na njega ne utječu sustavi za provođenje 1 opstrukciju zraka poput pregrada 1li slično.
Parenteral dosage forms can be prepared by dissolving the compound of the invention in a suitable liquid vehicle and filter sterilizing the solution before filling and scaling an appropriate vial or ampoule. 
Parenteralni dozirni oblici se mogu dobiti otapanjem spoja prema izumu u prikladnom tekućem sredstvu i sterilizacijom filtriranjem otopine prije punjenja i zatvaranja odgovarajuće bočice ili ampule.
The method of claim 14, wherein the method comprises coating the paper product with at least about 35 wt. % of a co-processed microfibrillated cellulose and inorganic particulate material composition on the paper product. 
prvi sjaj veći od drugog sjaja obloženog papirnog proizvoda koji sadrži mješavinu za oblaganje koja ne sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala; i/ili
Cup as claimed in one of the preceding claims, characterized in that the wall section (4) can be adjoined at an edge (7) of the pre-cut part. Cup as claimed in claim 17, characterized in that the wall section (4) includes a flap serving as the handle. 
Spremnik (1) prema jednom od prethodnih patentnih zahtjeva, naznačen time da dio stijenke (4) može graničiti sa rubom (7) dijela koji prethodno odrezan, pri čemu se spomenuti rub proteže u smjeru omatanja čaše (1).
OH, oxo, -CN, halogen, -methyl, -ethyl, n-propyl, isopropyl, O-propyl, -C1-3-haloalkyl, three-, four, five- or six-membered cycloalkyl, Het, Hetaryl, -CO-N(CH3)2, -CO-NHCH3, -CO-NH2,-(C1-3-alkylene)-O-(C1-3-alkyl), -O- Het, which is optionally further substituted by one, two or three substituents X, whereby each X is selected from the group consisting of halogen, oxo, -O-C1-4-alkyl, -C1-4-haloalkyl, -O-(C1-4-alkylene)- Het, Het, -NH2, whereby each substituent X is optionally further substituted by one, two or three substituents of a group selected from oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl, and the pharmaceutically acceptable salts of the aforementioned compounds. 
OH, okso, -CN, halogen, -metil, -etil, n-propil, izopropil, n-butil, izobutil, tert-butil, O-metil, -O-etil, O-propil, O-butil, -C1-3-haloalkil, tročlani, četiri-člani, pet-člani ili šest-člani cikloalkil, Het, Hetaril, -CO-N(CH3)2, -CO-NHCH3, -CO-NH2, -(C1-3-alkilen)-O-(C1-3-alkil), O-Het, koji je opcionalno dalje supstituiran s jednim, dva ili tri supstituenta X, pri čemu je svaki X odabran iz skupine koja se sastoji od sljedećih: halogen, okso, -C1-4-alkil, -O-C1-4-alkil, -C1-4-haloalkil, -O-(C1-4-alkilen)-Het, Het, -NH2, pri čemu je supstituent X opcionalno dalje supstituiran s jednim, dva ili tri supstituenta iz skupine odabrane od okso, metila, etila, n-propila, izopropila, n-butila, izobutila i tert-butila, i farmaceutski prihvatljive soli od gore spomenutih spojeva.
The pharmaceutical composition according to claim 4, wherein the one or more additional therapeutic agents is selected from the group consisting of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, and combinations thereof. 
Farmaceutski sastav prema bilo kojem od zahtjeva 5 do 7, pri čemu dodatno terapeutsko sredstvo ili sredstva su izabrani iz grupe koja obuhvaća HIV inhibitore proteaze, HIV ne-nukleozidne inhibitore reverzne transkripcije, HIV nukleozidne inhibitore reverzne transkripcije, HIV nukleotidne inhibitore reverzne transkripcije, i njihove kombinacije.
The solid oral extended release pharmaceutical dosage form according to any of claims 1 to 16, wherein the dosage form comprises from about 5 mg to about 250 mg of hydrocodone bitartrate or 1 mg to 100 mg of hydromorphone hydrochloride, and / or wherein the dosage form comprises 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg, or 80 mg, 90 mg, 100 mg, 120 mg or 160 mg of hydrocodone bitartrate or 2 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 32 mg, or 64 mg of hydromorphone hydrochloride. 
Kruti oralni farmaceutski oblik doziranja s produljenim oslobađanjem prema bilo kojem od patentnih zahtjeva 1 do 16, naznačen time da oblik doziranja sadrži od oko 5 mg do oko 250 mg hidrokodon bitartrata ili 1 mg do 100 mg hidromorfon hidroklorida, i/ili pri čemu oblik doziranja sadrži 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg, ili 80 mg, 90 mg, 100 mg, 120 mg ili 160 mg hidrokodon bitartrata ili 2 mg, 5 mg, 7.5 mg, 10 meg, 15 mg, 20 mg, 25 mg, 30 mg, 32 mg, ili 64 mg hidromorfon hidroklorida.
The pharmaceutical composition according to claim 8, further comprising a nucleoside analogue. 
Farmaceutski sastav prema patentnom zahtjevu 3, dalje sadrži nukleotidni inhibitor NS5B polimeraze.
The compound according to claim 1, which is trans-3-{[3-(1-Benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]oxy}cyclobutanamine, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, naznačen time da je trans-3-([3-(1-benzofuran-2-il)imidazo[1,2-b]piridazin-6iljoksi)ciklobutanamin, ili stereoizomer, tautomer, N-oksid, hidrat, solvat, ili njegova sol, naročito njegova farmaceutski prihvatljiva sol.
The system of claim 2 wherein said heating device comprises an electromagnetic element to provide electromagnetic energy to said substance by an induction heating mechanism. 
Sustav iz patentnog zahtjeva 2, naznačen time, da navedeni grijaći uređaj sadrži elektromagnetski element koji osigurava elektromagnetsku energiju spomenutoj tvari pomoću indukcijskog mehanizma za grijanje.
According to another preferred embodiment of the inventive process, the at least one acid having a pKa of less than or equal to 2.5 is provided in the form of at least one H3O+-ion provider and 5 wt.-% to 50 wt.-%, based on the weight of calcium carbonate, of at least one acid anion, wherein the corresponding acid of the at least one acid anion has a pKa of less than or equal to 2.5 and said acid anion is capable of forming water-insoluble calcium salts. 
Postupak prema bilo kojem od zahtjeva 1 do 16, naznačen time da je najmanje jedna kiselina koja ima pK, od manje od ili jednako 2.5 dana u obliku: najmanje jednog davatelja HgO'-iona koji ima pK, od manje od ili jednako 2.5, pri čemu je odgovarajući kiseli anion sposoban formirati kalcijevu sol koja je topiva u vodi, te najmanje jednog aniona, koji je pružen u obliku soli topive u vodi ili vodikove soli, pri čemu odgovarajuća kiselina toga najmanje jednog aniona ima pK, od manje od ili jednako 2.5 i pri čemu je navedeni anion sposoban formirati kalcijeve soli koje nisu topive u vodi.
N -methylpyrrolidinone: an additional solvent; a cationic surfactant; and 
N-metilpirolidinon; dodatno otapalo; kationski surfaktant; i sredstvo za raspršivanje.
reaction between (4) and the compound (3) thereby obtaining the final product. 
HR P20130380 T1 c) reakcija spoja (4) i spoja (3) kojom nastaje produkt.
The method of claim 1, wherein the infection is caused by a Gram-negative bacteria. The method of claim 5, wherein the bacteria is selected from selected from Enterobactericeae, Bacteroidaceae, Pasteurellae, Pseudornonadaceae, Neisseriaceae, Rickettsiae, Moraxellaceae, any species of Proteeae, Acinetobacter spp., Helicobacter spp., Campylobacter spp., and Vibrionaceae. 
Spoj za uporabu prema patentnom zahtjevu 3, ili uporabu prema patentnom zahtjevu 4, naznačen time da je zaraza uzrokovana Gram-negativnom bakterijom izabranom od FEnterobactericeae, Bacteroidaceae, Vibrionaceae, Pasteurellae, Pseudomonadaceae, Neisseriaceae, Rickettsiae, Moraxellaceae, bilo koja vrsta Proteeae, Acinetobacter spp., Helicobacter spp., i Capylobacter spp.
A compound according to claim 1 or 2, wherein any Ar may be substituted with one or more substituents independently selected among halogen, C1-6-alk(en/yn)yl, halo-C1-6-alk(en/yn)yl and C1-6-alk(en/yn)yloxy. 
Spoj prema bilo kojem od patentnih zahtjeva 1-6, naznačen time što svako Ar može biti supstituirano sa jednim ili više supstituenata koji su nezavisno izabrani od halogena, C1-6-alk(en/in)il, halo-C1-6-alk(en/in)il i C1-6-alk(en/in)iloksi.
The stabilization device of claim 1, wherein the sleeve is sized and dimensioned to extend past a valve clamp of the working channel when the distention valve is fitted onto the working channel. 
Stabilizacijska naprava iz patentnog zahtjeva 7, pri čemu se veličina i dimenzije rukavca protežu preko klapne ventila radnog kanala kada je distencijski ventil pričvršćen na radnom kanalu.
condensing said gaseous reaction product to said liquid fuel; 
(c) -kondenziranju navedenog produkta plinovite reakcije u navedeno tekuće gorivo;
The method of claim 1, wherein the subject has an FPG of 125 mg/dl or above. 
(ii) daje razina FPG veća od 125 mg / dl;
wherein R1 and R2 independently represent a saturated or unsaturated, branched or straight chain alkyl group having between 7 and 23 carbon atoms and R3 represents an amide or ester bonding group. 
Pripravak za uporabu prema zahtjevu 8 ili zahtjevu 9, naznačena time, da fosfolipid obuhvaća takav fosfolipid koji je predstavljen općom formulom I, [image] pri čemu R1 i R2 neovisno predstavljaju zasićenu ili nezasićenu, razgranatu ili ravnolančanu alkil skupinu koja ima između 7 i 23 ugljikova atoma a R3 predstavlja amidnu ili estersku vezujuću skupinu.
The system for fastening gems to a watch dial according to claim 1, wherein the peripheral edges of the openings of the two plate-shaped elements have the same inclination as corresponding upper and lower peripheral portions of the gems intended to be fastened to the dial in the seats formed by said openings facing each other. 
Sustav za pričvršćivanje dragulja na brojčanik ručnog sata u skladu s patentnim zahtjevom 1, naznačen time što periferni rubovi (32, 33) otvora (30, 31) dva pločasta elementa (23, 24) imaju isti nagib kao odgovarajući gornji i donji periferni dijelovi dragulja koje treba pričvrstiti na brojčanik u sjedištima koja čine navedeni otvori (30, 31) okrenuti jedni prema drugima.
In one embodiment, it is preferred for the compounds of the invention possessing the combined effect of serotonin reuptake inhibition and norepinephrine reuptake inhibition as described above, that such compounds are not also dopamine reuptake inhibitors. 
U jednom obliku preferira se za spojeve izuma koji posjeduju kombinirani učinak inhibicije re-apsorpcije serotonina i norepinefrina kako je to gore opisano da nisu, istodobno i inhibhori re-apsorpcije dopamina.
Another subject of the present invention is a process for producing a compound according to formula (2) or salt thereof 
8. Postupak za proizvodnju spoja prema sljedećoj formuli (2) ili njegove soli. po
calculating the percentage of brominated tyrosine in the glatiramer acetate. The subject invention also provides a process for preparing a pharmaceutical composition containing a mixture of polypeptides which do not all have the same amino acid sequence, where each polypeptide consists essentially of glutamic acid, alanine, tyrosine and lysine, wherein the mixture has a predetermined percentage of brominated tyrosine acceptable for inclusion in a pharmaceutical composition, which comprises obtaining a batch of a mixture of polypeptides having nonuniform amino acid sequences, where each polypeptide consists essentially of glutamic acid, alanine, tyrosine and lysine; 
Postupak za pripremanje farmaceutskog sastava koji sadrži glatiramer acetat, naznačen time, da glatiramer acetat ima predodređeni postotak bromiranog tirozina, prihvatljivog za uključivanje u farmaceutski sastav, koji postupak sadrži dobivanje šarže glatiramer acetata; mjerenje postotka bromiranog tirozina šarže postupkom koji sadrži a) hidroliziranje šarže da se dobije hidrolizat; b) eluiranje hidrolizata preko kromatografske kolone;
The method of claim 8, wherein the reagent is selected from the group consisting of an antibody, a fragment of an antibody or of an antibody derivative. 
Postupak prema zahtjevu 8, naznačen time, da je reagens odabran iz skupine koja se sastoji od protutijela, fragmenta protutijela ili derivata protutijela,
inhibition of spheroid growth of cells expressing ErbB3; 
inhibicija sferoidnog rasta stanica koje eksprimiraju ErbB3;
Thus, methods are provided to detect a protein in a sample, comprising the steps of: contacting a sample suspected of containing the protein with a molecule of the following structure: (X2i-1-Yi-X2i-Zi)n, wherein: 
Postupak za detektiranje proteina u uzorku, naznačen time, da obuhvaća korake: a) = dodavanje uzorka za kojeg se sumnja da sadržava protein s molekulom slijedeće strukture:
p is 1. A compound according to Claim 1 selected from: 
Spoj prema zahtjevu 1, naznačen time, da je on odabran iz skupine koju čine:
A method for the preparation of the compound of formula I or a salt thereof comprising reacting a compound of formula VIa (i.e. 
Postupak pripreme spoja formule I ili njegove soli koji obuhvaća reakciju spoja formule Vla (tj.
The gun stock according to claim 7, characterized in that said small plate has a front part that is fork-shaped and is adapted to engage said mushroom head; a rear part of the small plate being shaped so as to allow an easy grip and handling of the small plate by the user; said small plate further comprising at least one slot that engages protrusions formed in the structure and acting as stop and retention members for said small plate; said small plate being able to slide between a locking position of said mushroom head and a position in which said front fork-shaped part releases said mushroom head, allowing the separation of said cheek rest from said stock body. 
Kundak u skladu s patentnim zahtjevom 7, naznačen time što navedena mala ploča ima prednji dio (171), koji je viličastog oblika 1 prilagođen je za međudjelovanje s navedenom gljivastom glavom; gdje je stražnji dio (172) male ploče takvog oblika da korisniku omogući lako hvatanje i rukovanje malom pločom; gdje navedena mala ploča dodatno sadrži najmanje jedan utor (173), koji međudjeluje s izbočinama (33, 34), načinjenim u strukturi, koje djeluju kao elementi za zaustavljanje i zadržavanje navedene male ploče; gdje navedena mala ploča može klizati između zabravljujućeg položaja navedene gljivaste glave i položaja u kojem navedeni prednji viličasti dio otpušta navedenu gljivastu glavu, omogućujući odvajanje navedenog naslona za obraz od navedenog tijela kundaka.
Figure 7 is a diagram showing the connection of the receiver, used in the present invention, to the bow thruster of the boat; 
Slika 7 je dijagram koji prikazuje spoj prijemnika, koji se koristi u opisanom izumu, i krmenog potiskivača plovila;
More specifically, the present invention further provides a method of reconstructing a tooth, comprising the step of 
Specifičnije, ovaj izum dalje prikazuje metodu rekonstrukcije zubi, a sastoji se od sljedećih koraka:
The antitumor agent according to claim 10, wherein the shRNA is bound to the outer membrane surface of the liposome. 
Antitumorsko sredstvo za uporabu prema zahtjevu 9, naznačeno time, da je shRNA spojena s vanjskom površinom membrane liposoma.
The obtained nail lacquer composition had a clear and homogeneous appearance and a yellowish color even after prolonged storage. 
Dobiveni pripravak laka za nokte imao je bistar i homogeni izgled te žućkastu boju, čak nakon produljenog uskladištenja.
The use of a kit according to claim 12, wherein said nucleic acid probes in (i) or pair of nucleic acid primers in (ii) are selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 13, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, and SEQ ID NO:12; or with at least 90% identity thereof. 
Upotreba kompleta u skladu s patentnim zahtjevom 12, naznačena time što se navedene nukleinskokiselinske sonde u (i) ili par nukleinskokiselinskih početnica u (ii) bira iz skupine koju čine SEQ ID NO: 2, SEQ ID NO: 13, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, te SEQ ID NO:12; ili s najmanje 90 % istovjetnosti prema njima.
Figure 1 represents such a sanding element in the form of a laminated disc 1. 
Slika 1 prikazuje takav element za brušenje koji ima oblik lameliranog diska 1.
or a pharmaceutically acceptable acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof, with the exception of the compound N-(5-((1H-pyrrolo[2,3-B]pyridine-2-yl)ethynyl)pyridine-2-yl)acetamide. 
ili njihova farmaceutski prikladna kiselinska adicijska sol, racemidna smjesa ili njihov odgovarajući enantiomer i/ili njihov optidki izomer i/ili stereoizomer, s izuzetkom spoja N-(5-((1H-pirolo[2,3-B]piridin-2-il) etinil) piridin-2-il)acetamida.
In one embodiment, the substitutions result in expression of histidines at positions 105, 106, 107, and 109. 
(a) na položaju odabranom iz 105, 106, 107, 109 1 njihove kombinacije;
Process for conditioning a gas stream from a gasifier, the thermal cracking of tars present in said gas stream and the steam reforming of the remaining carbon in said gas stream comprising the following steps: 
Postupak obrade struje plina iz rasplinjača, gdje toplinsko krekiranje katrana prisutnog u navedenoj struji plina i reformiranje vodenom parom preostalog ugljika u navedenoj struji plina uz pomoć reaktora u skladu s patentnim zahtjevima 1 do 8, naznačen time što se sastoji u sljedećim koracima:
A process according to claim 25 wherein step (a) comprises treating the mixture of isomers IIIa and IIIb with 4-dimethylaminopyridine (DMAP) to form the corresponding DMAP salts. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što se korak (a) sastoji u obradi smjese izomera IIIa i IIIb 4-dimetilaminopiridinom (DMAP) kako bi se dobilo odgovarajuće soli DMAP.
15 connecting strip A panel having mutually averted panel surfaces and a periphery which delimits the panel surfaces, comprising a series of parallelly positioned, elongated core elements (1, 1', 1 ",...), as well as material strips (2, 2', 2",...) which each comprise a portion located between respectively two neighboring core elements and at least one portion extending along one of the panel surfaces, characterized in that those portions of the material strips which extend along the panel surfaces extend over a plurality of core elements. 
Ploča, kojoj su površine ploče razmaknute jedna u odnosu na drugu i koja ima obrub koji ograničava površine ploče i koja ploča ima niz paralelno postavljenih, izduženih središnjih elemenata (1, 1', 1",...), kao i trake od materijala (2, 21,27,...), od kojih traka svaka ima predio koji je smješten između svakog od dva susjedna središnja elementa, 1 najmanje jedan predio koji se prostire duž jedne od površina ploče, naznačen time što se svaki od predjela trake od materijala, koji se prostire duž površina ploče, pruža preko više središnjih elemenata.
J Virol, 1998; 72: 8463-71 A stable mammalian lentiviral packaging cell line comprising at least one copy of an integration cassette stably integrated into its genome and at least one copy of an env gene, wherein said at least one integration cassette comprises: 
Proizvođačka stanična linija naznačena time da u svome genomu sadrži stabilno integrirane: i. barem jednu kopiju kazete za integraciju flankiranu AAV ITR, uključujući dvije kazete za ekspresiju, pri čemu prva kazeta za ekspresiju kodira lentivirusne gag i pol gene, a druga lentivirusni rev gen i selekcijsku oznaku ii. barem jednu kopiju env gena ili. prijenosni vektor.
the variable light chain sequence of SEQ ID NO: 85 and variable heavy chain sequence of SEQ ID NO: 99; 
(a) varijabilno područje slabog lanca od sekvence SEQ ID NO: 85, i varijabilno područje jakog lanca od sekvence SEQ ID NO: 99;
A compound of either of the following formulae: wherein R5 and R6 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, alkylaryl, arylalkyl, heterocyclic and heteroaryl groups, or R5 and R6, together with the nitrogen to which they are attached, form a 3- to 6-membered heterocyclic compound containing 1-4 heteroatoms. 
i 7, gdje svakog od Rs i Rg se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne, heterocikličke i heteroarilne skupine, ili Rs i R4, zajedno s dušikom na kojeg su vezani, tvore 3- do 6-eročlani heterociklički spoj s 1-4 heteroatoma, gdje:
H, alkyl such as an isobutyl group, olefinic, aromatic group such as Ph, O-alkyl, O-olefinic, or O-aromatic 
H, alkil kao što je izobutil skupina, olefin skupina, aromatska skupina kao što je Ph, O-alkil, Oolefinska ili O-aromatska R:
The compound according to any of claims 1 to 8 or a pharmaceutically acceptable salt thereof for use in a method for treatment of a pathology selected from the group consisting of psychiatric and neurological disorders; neurodegenerative disorders; metabolic disorders; addiction, dependence, abuse relapse and related disorders; bladder and gastrointestinal disorders; hepatic diseases such as steatosis; non-alcoholic steatohepatitis (NASH), liver cirrhosis; alcoholic steatosis; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; obesity; autoimmune hepatitis and encephalitis; pain or reproductive disorders and skin inflammatory and fibrotic diseases. 
12. Tvar za uporabu u skladu s patentnim zahtjevom 11, pri čemu je navedena patologija odabrana iz grupe koja se sastoji od psihijatrijskih 1 neuroloških poremećaja, neurodegenerativnih poremećaja, metaboličkih poremećaja, loših navika, ovisnosti, relapsa zlouporabe i povezanih poremećaja, poremećaja mjehura i hastrointestinalnih poremećaja, bolesti jetre kao što je steatoza, nealkoholnog steatohepatitisa (NASH), ciroze jetre, alkoholne steatoze, upalnih bolesti, kardiovaskularnih bolesti, neuropatija, glaukoma, spastičnosti, raka, osteoporoze, pretilosti, autoiminog hepatitisa 1 encefalitisa, boli ili reproduktivnih poremećaja i upalnih 1 fibrotičnih bolesti kože.
Conventional taste masking techniques, such as the use of sweeteners, amino acids, and flavoring agents often are unsuccessful in masking the taste of highly bitter drugs and, consequently, other techniques need to be exploited for effectively masking the taste of these antibiotics. 
Uobičajene tehnike maskiranja, poput uporabe zaslađivača, amino kiselina 1 sredstava za korekciju okusa često nisu uspješne u maskiranjuu okusa izuzetno gorkih lijekova 1 stoga je potrebno istražiti ostale tehnike koje bi bile uspješnije u maskiranju okusa tih antibiotika.
said air sparging is continued until the pre-harvest or harvested culture fluid is at least about 30% saturated with air, or is between about 100% saturated to about 30% saturated with air; or 
Postupak prema patentnom zahtjevu 3, naznačen time, da se propuhivanje zrakom nastavlja sve dok sakupljeni fluid stanične kulture ne bude zasićen zrakom najmanje 30%.
The recombinant DNA molecule of claim 1, wherein said DNA molecule comprises SEQ ID NO:1 and SEQ ID NO:2. 
se prva spomenuta DNA molekula sastoji od SEQ ID NO: 6, a druga se spomenuta DNA molekula sastoji od SEQ ID NO: 7; ili
An isolated nucleic acid molecule according to claim 9 comprising: 
Izolirana molekula nukleinske kiseline prema zahtjevu 6 naznačena time što se sastoji od: